Different approach to M descriptor for future staging of oligometastatic disease in SCLC: A cross-sectional survival analysis
Authors:
- Melahat Uzel ŞenerMŞMelahat Uzel Şener
- Pınar Akın KabalakPKPınar Akın Kabalak
- Suna KavurgacıSKSuna Kavurgacı
- Nilgün Yılmaz DemirciNDNilgün Yılmaz Demirci
- Derya KızılgözDKDerya Kızılgöz
- Fazlı YanıkFYFazlı Yanık
- Sinem ErminSESinem Ermin
- Yasemin SöylerYSYasemin Söyler
- Yekta Altemur KaramustafaoğluYKYekta Altemur Karamustafaoğlu
- Demet Türkay PaknaDPDemet Türkay Pakna
- Ahmet DumanlıADAhmet Dumanlı
- Ülkü YılmazÜYÜlkü Yılmaz
- 5 November 2024
- journal article
- research article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 27 (6) , 2750-2760
Abstract
Purpose This study aimed to investigate the impact of oligometastasis and the M descriptor on survival in small cell lung cancer (SCLC). Methods This multicenter, retrospective study included patients with newly diagnosed extensive-stage SCLC(ES-SCLC) from 2010 to 2020. Subgroups: Group 1: single metastasis in a single organ, Group 2: 2–5 metastases in a single organ, Group 3: 6 or more metastases in a single organ, and Group 4: metastases in two or more organs. This classification was based on the 9th Staging-M descriptor. Three-year progression-free survival (PFS) and overall survival (OS) analyses were conducted. Results The mean age of the 439 patients was 62 ± 10 years, and 89.5% of them were male. The mean PFS for Groups 1, 2, 3, 4 was 10.7 months (95% CI 8.9–12.5), 7.5 months (95% CI 5.6–9.4), 4.3 months (95% CI 2.9–5.7), and 5.4 months (95% CI 4.7–6.1), respectively. PFS in Group 2 was significantly higher. The mean OS for Groups 1, 2, 3, 4 was 13.3 months (95% CI 11.2–15.3), 9.5 months (95% CI 7.1–11.9), 7.1 months (95% CI 4.5–9.7), and 6.9 months (95% CI 6.0–7.9), respectively. OS in Group 1 was significantly higher. OS and PFS in the M1b group were significantly higher than in the M1c1 and M1c2 groups (p < 0.05) with no statistical difference between the M1c1 and M1c2 groups. Conclusion There is no significant difference in survival between the M1c1 and M1c2 groups. In ES-SCLC, the number of metastases may be a more predictive factor for prognosis than the number of metastatic organs.Keywords
This publication has 24 references indexed in Scilit:
- The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung CancerJournal of Thoracic Oncology, 2024
- The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung CancerJournal of Thoracic Oncology, 2024
- Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of ImmunotherapyCurrent Treatment Options in Oncology, 2020
- Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus ReportJournal of Thoracic Oncology, 2019
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trialThe Lancet, 2019
- Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trialThe Lancet, 2019
- Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung CancerJAMA Oncology, 2017
- The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung CancerJournal of Thoracic Oncology, 2016
- Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trialThe Lancet, 2015
- Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer—what limits limited disease?Lung Cancer, 2002